Format

Send to

Choose Destination
See comment in PubMed Commons below
Reumatol Clin. 2011 Nov-Dec;7(6):392-6. doi: 10.1016/j.reuma.2011.06.007. Epub 2011 Oct 21.

[Efficacy and safety of abatacept in patients with rheumatoid arthritis and no prior treatment with biologics].

[Article in Spanish]

Author information

1
Servicio de Reumatología, Hospital Universitario Reina Sofía, Córdoba, España.

Abstract

Abatacept (ABA) is a recombinant human fusion protein that blocks co-stimulation signals on T lymphocytes, impeding their activation. Randomized and controlled trials examining efficacy and safety have been performed with ABA combined with methotrexate (MTX), vs MTX monotherapy and vs infliximab (IFB) combined with MTX in patients with Rheumatoid Arthritis and who are naïve to biologic therapy. ABA has shown to be more effective than MTX and at least as effective as IFB+MTX, in terms of activity and clinical remission, physical function and reduction in radiological progression. Safety data at 7 years have shown that the drug is comparable to MTX in monotherapy and safer than the IFB+MTX combination, although infections still constitute the main risk when using ABA. This review summarizes the safety and efficacy data of the AIM, ATTEST, Phase IIb IM101-100 and AGREE trials.

PMID:
22078698
DOI:
10.1016/j.reuma.2011.06.007
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Ediciones Doyma, S.L.
    Loading ...
    Support Center